Citigroup
ROIV icon

Citigroup’s Roivant Sciences ROIV Stock Holding History

Citigroup’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$78.7M Buy
2,225,190
+689,080
+45% +$20.4M 0.03% 566
2026
Q1 		$42.6M Sell
1,536,110
-175,634
-10% -$4.51M 0.02% 699
2025
Q4 		$37.1M Sell
1,711,744
-47,891
-3% -$945K 0.02% 769
2025
Q3 		$26.6M Buy
1,759,635
+272,936
+18% +$3.38M 0.01% 914
2025
Q2 		$16.8M Buy
1,486,699
+766,312
+106% +$8.31M 0.01% 1063
2025
Q1 		$7.27M Buy
720,387
+81,482
+13% +$881K ﹤0.01% 1607
2024
Q4 		$7.56M Buy
638,905
+342,139
+115% +$4.05M ﹤0.01% 1596
2024
Q3 		$3.42M Buy
296,766
+145,730
+96% +$1.66M ﹤0.01% 2180
2024
Q2 		$1.6M Sell
151,036
-698,009
-82% -$7.65M ﹤0.01% 2543
2024
Q1 		$8.95M Buy
849,045
+481,139
+131% +$5.19M 0.01% 1320
2023
Q4 		$4.13M Buy
367,906
+41,475
+13% +$404K ﹤0.01% 1718
2023
Q3 		$3.81M Buy
326,431
+102,279
+46% +$1.16M ﹤0.01% 1575
2023
Q2 		$2.26M Sell
224,152
-388,424
-63% -$3.47M ﹤0.01% 2088
2023
Q1 		$4.52M Buy
612,576
+482,220
+370% +$3.97M ﹤0.01% 1556
2022
Q4 		$1.04M Buy
130,356
+118,945
+1,042% +$662K ﹤0.01% 2579
2022
Q3 		$37K Sell
11,411
-9,541
-46% -$36.9K ﹤0.01% 4515
2022
Q2 		$85K Buy
20,952
+15,203
+264% +$60.3K ﹤0.01% 4299
2022
Q1 		$28K Buy
5,749
+5,447
+1,804% +$35.9K ﹤0.01% 4983
2021
Q4 		$3K Buy
+302
New +$2.51K ﹤0.01% 5715

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Citigroup's ROIV Position: Q2 2026 in Review

Citigroup increased its Roivant Sciences (ROIV) stake by 45% in Q2 2026, buying an estimated $20.4M and bringing the position to 2,225,190 shares worth $78.7M. The position accounts for 0.03% of the portfolio, ranked #566.

Citigroup first reported a position in ROIV in Q4 2021 and has held it in 19 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Citigroup held 2,225,190 shares of Roivant Sciences worth $78.7M as of Q2 2026.
  • Citigroup bought 689,080 Roivant Sciences shares in Q2 2026, an estimated $20.4M.
  • Roivant Sciences made up 0.03% of Citigroup's portfolio in Q2 2026, its #566 holding.
  • Citigroup first reported a position in Roivant Sciences in Q4 2021 and has held it in 19 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.